Clinical Trials · NCT02626507
Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
- Phase
- Phase 1
- Recruitment status
- Unknown
- Sponsor
- Hoffman Oncology
- Enrollment
- 18
- Start date
- Jan 2016
- Locations
- 2 sites, United States
- Primary endpoint
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0